Summary
The antihypertensive effect of a new sustained-release matrix formulation of verapamil 200 mg was investigated in a dose-response study in patients with mild to moderate essential hypertension. Noninvasive ambulatory blood pressure measurements were recorded over 24 h in 6 patients with diastolic blood pressure ≥100 mmHg. The patients received sustained-release verapamil 200 mg once daily and twice daily in a randomized order. Each medication period lasted 2 weeks. Verapamil 200 mg twice daily had a better antihypertensive effect than the same dose once daily. After a 6-week placebo period 27 patients with a diastolic blood pressure ≥100 mmHg were included in a double-blind clinical trial. The patients received sustained release verapamil 200 mg once daily and twice daily in a randomized crossover manner. Each medication period lasted 6 weeks, with an intervening 6-week placebo period. A diastolic blood pressure of ≤95 mmHg was achieved in 6 patients with the once-daily regimen and in 14 with the twice-daily regimen. The mean fall in diastolic blood pressure was 4 and 9 mmHg, respectively (p<0.05). We conclude that sustained-release verapamil 200 mg once daily gives a satisfactory blood pressure response only in a minority of patients, while 200 mg twice daily has a significantly better antihypertensive effect. Both doses were well tolerated.
Similar content being viewed by others
References
Lewis GRJ, Morley KD, Lewis BM, Bones PJ (1978) The treatment of hypertension with verapamil. NZ Med J 87: 351–354
Leonetti G, Sala C, Bianchini C, Terzoli L, Zanchetti A (1980) Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol 18: 375–382
Bühler FR, Hulthén L, Kiowski W, Müller FB, Bolli P (1982) The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 4: 350–357
Gould BA, Mann S, Kieso H, Bala Subramanian V, Raftery EB (1982) The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65: 22–27
Rawlins MD (1979) Drug absorption and bioavailability: the 1980's. In: Prescott LF, Nimmo WS (eds) Drug absorption. ADIS Press, Sydney
Schütz E, Riem Ha H, Bühler FR, Follath F (1982) Serum concentration and antihypertensive effect of slow-release verapamil. J Cardiovasc Pharmacol 4 [Suppl 3]: S346–349
Corea L, Bentivoglio M, Verdechia P, Bianchini C (1983) Long term verapamil therapy in mild-to-moderate hypertension. Randomized study of normal and slow-release formulations. Acta Ther 9: 263–271
Mattila J, Mäntylä R, Taskinen J, Männistö P (1985) Pharmacokinetics of sustained-release verapamil after a single administration and at steady-state. Eur J Drug Metabol Pharmacokinet 10: 133–138
Pickering TG, Harshfield GA, Kleinert HD, Blank S, Laragh JH (1982) Blood pressure during normal daily activities, sleep and exercise. Comparison of values in normal and hypertensive subjects. J Am Med Assoc 247: 992–996
Weber MA, Drayer JIM, Nakamura DK, Wyle FA (1984) The circadian blood pressure pattern in ambulatory normal subjects. Am J Cardiol 54: 115–119
Drayer JIM, Weber MA, DeYoung JL, Wyle FA (1982) Circadian blood pressure patterns in ambulatory hypertensive patients. Effects of age. Am J Med 73: 493–499
Mann S, Millar Craig MW, Balasubramanian V, Raftery EB (1980) Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol 10: 443–447
Jacot-des-Combes B, Brunner HR, Waeber B, Porchet M, Biollaz J (1984) Blood pressure variability in ambulatory hypertensive patients; effect of β-blocking agents and/or diuretics. J Cardiovasc Pharmacol 6: 263–266
Midtbø K, Hals O (1980) Verapamil in the treatment of hypertension. Curr Ther Res 27: 830–838
Anavekar SN, Christophidis N, Louis WJ, Doyle AE (1981) Verapamil in the treatment of hypertension. J Cardiovasc Pharmacol 3: 287–292
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nissinen, A., Koistinen, A., Tuomilehto, J. et al. Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study. Eur J Clin Pharmacol 31, 255–259 (1986). https://doi.org/10.1007/BF00981120
Issue Date:
DOI: https://doi.org/10.1007/BF00981120